Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last month.
Eli Lilly and Co.
-
Q&A with the head of Lilly manufacturing, who meticulously tracks gains in work, life
“People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of management.”
Read More -
Eli Lilly to spend $27B on four new manufacturing sites
The new manufacturing sites are expected to create create 3,000 pharmaceutical jobs and nearly 10,000 construction positions during the buildout.
Read More -
UPDATE: Lilly reports robust Q4, full-year earnings
Lilly’s fourth-quarter earnings, released before the market opened Thursday, surpassed analysts’ expectations by millions.
Read More -
Roche gets FDA clearance for test of emerging cardiovascular disease risk factor
Lipoprotein(a) has long been recognized as a critical marker for people at risk of cardiovascular disease. However, the health care industry has lacked the tools to tackle the problem.
Read More
Articles
Lilly’s Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly and Co.’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the medications.
‘Innovation at every stage’: Lilly to invest up to $250M in broadened alliance with Purdue University
The extended partnership holds the potential to be the largest industry-academic agreement of its kind in the United States, Purdue President Mung Chiang said.
Lilly shuffles roles amid growth in U.S. investment, diabetes and obesity treatments
The company has announced more than $50 billion in new U.S. manufacturing investments since 2020.
Lilly chief scientist talks drugmaker’s new $4.5B campus, recruiting and innovation
Chief Scientific Officer Dr. Daniel Skovronsky talked with the IBJ about his hopes for the Lilly Medicine Foundry, which the Indianapolis-based drugmaker broke ground on this week.
Lilly breaks ground on $4.5B foundry campus in Lebanon’s LEAP District
Officials from the Indianapolis-based drugmaker said the Lilly Medicine Foundry will help streamline the process of discovering new medicines and getting them to patients.
UPDATE: Lilly shares tumble after missing analyst earnings expectations
The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on existing tariff and trade policies.
Report: Americans spent $71B on GLP-1 drugs in 2023
By 2023, semaglutide (Ozempic, Rybelsus and Wegovy) and tirzepatide (Mounjaro) products made up 70% of all U.S. GLP-1 spending.
Lilly promises to make weight-loss pill in United States in reshoring push
By making the expected blockbuster pill in the U.S., Lilly may be able to avoid the impact of Trump’s sweeping tariffs, including possible levies on pharmaceutical products.
Lilly stock soars after weight-loss pill’s trial results rival Ozempic’s shot
Trial data data showed Lilly’s experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.
Trump orders new efforts to lower drug prices
Trump’s order contains proposals to further lower the cost of insulin, importing more low-cost drugs and streamlining the federal approval process for some drugs.
Irish pharma exports to United States surge amid tariff threat
It was the second straight sizable increase, suggesting that U.S. drug makers with Irish manufacturing hubs like Indianapolis-based Eli Lilly and Co. could be stockpiling products ahead of any tariffs on the sector.
Pfizer ends development of potential pill obesity treatment
Pfizer had been hoping the once-daily pill treatment would give it an edge over leading weight-loss treatments like Zepbound from Eli Lilly and Co. and Novo Nordisk’s Wegovy, which are injectable.
Lilly sues Indianapolis clinic for selling split doses of popular weight-loss drugs
The drugmaker accuses Premier Weight Loss of risking patients’ health by selling altered, unsterile versions of its blockbuster drugs Mounjaro and Zepbound.
Skyrocketing cost of weight-loss drugs has state Medicaid programs looking for solution
At least 14 states already cover the cost of GLP-1 medications for obesity treatment for patients on Medicaid. Indiana is not one of them.
Trump administration nixes plan to cover anti-obesity drugs through Medicare
President Trump’s predecessor, Joe Biden, proposed a rule in late November after Trump won re-election that would have extended coverage of drugs like Zepbound and Wegovy.
Purdue president: Universities must explore private alternatives to federal funding
Amid uncertainty around federal research funding, universities must explore private support, Purdue University President Mung Chiang told an tech industry group on Tuesday.
European regulators says Lilly Alzheimer’s drug shouldn’t get marketing approval
The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it.
Lilly adds online education, care services for Alzheimer’s to LillyDirect platform
The company said its goal is to reduce wait times for patients seeking access to specialists, creating more opportunities for early diagnosis and intervention.
Zepbound raises profile of Lilly’s direct-to-consumer sales initiative
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to connect directly with consumers on the platform since.